Staff Members - Benha University
Spexin alleviates hypertension, hyperuricaemia, dyslipidemia and insulin resistance in high fructose diet induced metabolic syndrome in rats via enhancing PPAR-ɣ and AMPK and inhibiting IL-6 and TNF-α
• 2021
Publication Information
Authors
Mona A. Said, Naglaa Y. Nafeh and Hend A. Abdallah
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
International
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Spexin is a novel peptide implicated in obesity and energy homeostasis. The objective of the current
study was to evaluate the effect of spexin on blood pressure, insulin resistance, and dyslipidemia in
rats with metabolic syndrome (MS) induced by high-fructose diet (HFD) and the possible underlying
mechanism. Forty adult male rats were randomly assigned into four equal groups; Control, Spexin,
HFD and HFDþ spexin. Induction of the MS with HFD was associated with increased body mass index,
elevated blood pressure, blood glucose, insulin, uric acid, advanced glycation end products and insulin
resistance, interlekin-6, tumour necrosis factor-alpha together with dyslipidemia, low-serum spexin,
peroxisome proliferator-activated receptors-gamma (PPAR-Ç) and adenosine monophosphate-activated
protein kinase (AMPK). Spexin attenuated MS-induced deleterious effects which can be attributed to
activation of PPAR-Ç and AMPK as well as inhibiting inflammation. These findings indicate that spexin
could be a beneficial complementary agent for metabolic syndrome treatment
study was to evaluate the effect of spexin on blood pressure, insulin resistance, and dyslipidemia in
rats with metabolic syndrome (MS) induced by high-fructose diet (HFD) and the possible underlying
mechanism. Forty adult male rats were randomly assigned into four equal groups; Control, Spexin,
HFD and HFDþ spexin. Induction of the MS with HFD was associated with increased body mass index,
elevated blood pressure, blood glucose, insulin, uric acid, advanced glycation end products and insulin
resistance, interlekin-6, tumour necrosis factor-alpha together with dyslipidemia, low-serum spexin,
peroxisome proliferator-activated receptors-gamma (PPAR-Ç) and adenosine monophosphate-activated
protein kinase (AMPK). Spexin attenuated MS-induced deleterious effects which can be attributed to
activation of PPAR-Ç and AMPK as well as inhibiting inflammation. These findings indicate that spexin
could be a beneficial complementary agent for metabolic syndrome treatment